Autifony Therapeutics Limited
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Autifony Therapeutics Limited
It is time for In Vivo's 16th annual Deals of the Year contest. We've selected 12 nominees across three categories – Top M&A, Top Alliance and Top Financing – and you get to pick the winners.
Deal Snapshot: The two companies will collaborate on drugs targeting two ion channels in neurological disorders, with Autifony receiving upfront and milestone payments up to $770.5m.
New company licenses obicetrapib from Amgen after previous companies’ setbacks in CETP class and works with FDA on a Phase III protocol. BMS buys protein-engineering specialist Forbius.
The German group has signed a second deal with Gubra to develop poly-agonist peptides for obesity that could be worth up to €240m.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.